本文检测了４５例ＧＤ，１００例健康对照组血清ＴＮＦ－α水平，结果ＧＤ患者血清ＴＮＦ－α水平显著升高（Ｐ＜０．０１）。与其ＦＴ３，ＦＴ４，ＴＧＡＢ，ＴＭＡＢ水平及其甲吸率无相关性。升高的水平与病程长短和甲状腺大小有关。 ＧＤ患者１３１Ｉ治疗前后血清：ＦＮＦ－α水平无明显变化，(１３１)~Ｉ治疗后不同效果组治疗前血清ＴＮＦ－α水平无明显差异。表明ＧＤ患者血清ＴＮＦ－α水平升高； ＧＤ的“功能缓解”与“免疫缓解”不同步；ＴＮＦ－α不影响ＧＤ患者对碘的摄取及其对腆的敏感性。 In this paper, 45 cases of GD, 100 cases of healthy control serum TNF-α levels, the results of GD patients with serum TNF-α levels were significantly increased (P <0.01). There was no correlation between FT3, FT4, TGAB and TMAB levels and their rates of askerosis. Elevated levels and duration of disease and thyroid size related. There was no significant difference in serum FNF-α levels between before and after treatment with 131I in GD patients. There was no significant difference in serum TNF-α levels before and after 131I treatment. The level of serum TNF-α in patients with GD was higher than that in patients with GD. The “functional remission” of GD was not synchronized with “immune response”. TNF-α did not affect the uptake of iodine and its sensitivity to asthma in GD patients.